ILD-SARDs Registry and Biorepository (NCT05007340)
Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases (ILD-SARDs) Registry and Biorepository
🩺 Plain-English Summary (8th-Grade Level)
A complex interaction between demographic, environmental and genetic mechanisms impact the onset, severity and outcome of ILD-SARDs through dysregulation of the immune system and lung pro-biotic pathways. Comorbidity and genetic risk indicate that there are overlapping pathogenic mechanisms among SARDs, some of which underlie ILD in different SARDs. The purpose of this biobank is to study the clinical, pathological, laboratory, and imaging characteristics of SARDs patients with lung involvement. This will help identify as unique features underlying lung involvement in SARDs. In addition, this may lead to the discovery of novel mechanisms of disease and potentially novel targets of treatment for SARDs patients with lung disease.
Who can join: Review the eligibility criteria below.
Location: RI-MUHC — Montreal, Quebec
Age range: 18 Years
🧪 Interventions in This Study
- Blood draws (OTHER)
- Other biological samples to biobank (skin, lung and muscle biopsies; bronchoalveolar lavage (BAL fluid) (OTHER)
- Clinical data collection (OTHER)
- Genetic data/DNA/RNA (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- RI-MUHC — Montreal, Quebec
📞 Contact the Study Coordinator
Phone: (514) 934-1934
Email: deborah.assayag@mcgill.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Interstitial Lung Disease
- Genentech Validation Tool for Pulmonary Fibrosis — New York, New York
- FAPI PET for Lung Fibrosis — Los Angeles, California
- Interstitial Lung Disease Research Unit Biobank — Kansas City, Kansas
- Hyperpolarized 129Xe MRI for Imaging Pulmonary Function — Durham, North Carolina
- Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough — Rochester, Minnesota
- Pulmonary Hypertension SOLAR — Durham, North Carolina
Explore by condition: All Interstitial Lung Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.